Tuesday, June 21, 2016

Reuters: Oncology Venture's immuno-oncology drug APO010 gets EUROSTARS grant (via EUREKA)

Up to 6 million Norwegian crowns ($715,879.40) has been granted by the Norwegian Research Council through the EUROSTARS program for the development of Oncology Venture's immuno-oncology product APO010. The grant for APO010 was received by Smerud Medical Research International AS (SMERUD), Oncology Venture's co-development partner, which in addition to co-funding the trial will also use its contract research division to manage the clinical trial.

from EUROPA - Syndicated Research News Feed http://ift.tt/28Mkn0F

No comments:

Post a Comment